CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will be presenting at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City.
新加坡， 2023年11月14日 /PRNewswire/ — CytoMed Therapeutics Limited（纳斯达克股票代码：GDTC）（“CytoMed” 或 “公司”），a 新加坡总部位于基准公司的生物制药公司专注于利用其专有技术开发用于治疗各种癌症的新型捐赠者衍生的基于细胞的异基因免疫疗法，今天宣布将在The Benchmark Company的第12届大会上发表演讲第四 年度发现一对一投资者会议即将举行 12 月 7 日，星期四第四，2023 年在纽约体育俱乐部举行 纽约市。
The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which CytoMed Therapeutics will be participating in one-on-one meetings with investors and analysts throughout the day.
该会议以独特的一对一形式为新兴成长型和充满活力的上市公司提供了与机构和个人投资者接触的机会，在此期间，CytoMed Therapeutics将全天参加与投资者和分析师的一对一会议。
To schedule a one-on-one meeting with the company, you may submit your request online via the link provided upon registration. To register for the conference, please visit
要安排与公司的一对一会议，您可以通过注册时提供的链接在线提交申请。要报名参加会议，请访问
About The Benchmark Company
关于基准公司
The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm's sales, trading, and equity research capabilities. .
Benchmark Company是一家以机构为中心、以研究为导向、销售交易和投资银行业务 公司。我们 成立于 1988 年，总部位于纽约 Ci试试。O我们的重点是通过筹集资金、提供战略咨询服务、进行有见地的研究以及利用公司的销售、交易和股票研究能力发展机构赞助来促进企业客户的长期成功。 。
About CytoMed Therapeutics Limited (CytoMed)
关于 CytoMed Therapeutics 有限公司（CytoMed
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. For more information, please visit and follow us on Twitter @CytomedSG,on LinkedIn, and Facebook
CytoMed 成立于 2018 年，从科学、技术和研究署 (A*STAR) 分拆出来， 新加坡的 公共部门领先的研发机构。它是一家生物制药公司，专注于利用其许可的专有技术来开发用于治疗人类癌症的新型细胞免疫疗法。新技术的开发受到现有CAR-T疗法在治疗血液恶性肿瘤方面的临床成功以及将CAR-T原理推到实体瘤治疗方面当前的临床局限性和商业挑战的启发。欲了解更多信息，请在 Twitter @CytomedSG、LinkedIn 和 Facebook 上访问并关注我们
SOURCE CytoMed Therapeutics Limited
来源 CytoMed 治疗有限公司
译文内容由第三方软件翻译。